 As a part of the Amphastar Pharmaceuticals clinical development plan, the current study examines the clinical efficacy of A004, Armstrong Pharmaceuticals Albuterol HFA oral inhalation MDI, in preventing EIB in adolescent and adult asthmatic patients. 